Clubmoss for Health & Longevity - Quick Reference Sheet
evipedia.ai
← Back

Clubmoss for Health & Longevity

Created on 08/25/2026 – Quick Reference based on Evidence Review created using AI4L / Opus 5 – Audit

Clubmoss reaches most people as a purified compound that slows removal of the brain chemical carrying memory and attention signals. Combined study results favor memory in people with measurable impairment; the one carefully run Western study missed its main goal. Set against that: dose-related stomach upset, sweating, slower pulse, broken sleep, and labels that rarely match contents. (Full Review)

Protocol

Nootropic intermittent dosing
50–200 micrograms
Taken only on days requiring sustained focus. Conventional Chinese clinical dosing is 200–400 micrograms daily in two divided doses. Neither approach is the default.
Best time of day
Morning, on rising
Peak blood level near one hour. The roughly 12-hour half-life makes a single morning dose adequate at 50–200 micrograms and reduces evening carry-over. A small meal reduces nausea.
Baseline biomarkers
Reversible causes corrected
Low vitamin B12, elevated homocysteine and untreated thyroid dysfunction are corrected first. Vascular disease, sleep apnea and depression each blunt response and are treated first.
Time to effect
Cognitive test scores
4–16 weeks
Measurable improvement in cognitive test scores in the trials took 4–16 weeks of continuous dosing.
Acute effects
1–2 hours
Acute cholinergic effects appear within one to two hours of a single dose; plasma appearance within 5–10 minutes.
Loss of effect
Days after stopping
Cognitive effects are symptomatic, not cumulative. The gain fades within days of stopping; nothing in the human record suggests a residual benefit.

Benefits

Contraindications
  • Pregnancy or breastfeeding
  • Prescription cholinesterase inhibitors (donepezil, rivastigmine, galantamine, pyridostigmine)
  • Resting heart rate below 50 beats per minute, sick sinus syndrome, second- or third-degree atrioventricular block without a pacemaker
  • Active peptic ulcer disease or gastrointestinal bleeding within the past 90 days
  • Poorly controlled asthma or chronic obstructive pulmonary disease at GOLD stage III or higher
  • Mechanical urinary outflow obstruction
  • Estimated glomerular filtration rate below 30 mL/min/1.73 m²
  • Within one week of planned general anesthesia; neuromuscular blockers such as succinylcholine
  • Occupational pesticide handling during application seasons
    •
Key Interactions
  • Anticholinergic medicines (oxybutynin, tolterodine, scopolamine, diphenhydramine, tricyclic antidepressants)
  • Beta blockers, non-dihydropyridine calcium channel blockers (verapamil, diltiazem), digoxin
  • Non-steroidal anti-inflammatory drugs (ibuprofen, naproxen) and other over-the-counter gastric irritants
  • Over-the-counter sleep aids and antihistamines (diphenhydramine, doxylamine)
  • Choline-donor supplements (alpha-glycerophosphocholine, citicoline, choline bitartrate)
  • Other cholinesterase-inhibiting botanicals (Bacopa monnieri, galantamine from Galanthus, Ginkgo biloba)
  • High-dose nicotine and organophosphate pesticide exposure
    •

Risk & Side Effects

  • High: Dose-related cholinergic side effects
    •
  • Medium: Mislabeled, adulterated, or contaminated products
    •
  • Low: Bradycardia, syncope, and fall-related injury; sleep disturbance and vivid dreaming
    •
  • Speculative: Bronchoconstriction in reactive airway disease; seizure-threshold effects; loss of effect with continuous daily use
    •

Monitoring

Marker Target Why
Resting heart rate 55–75 beats per minute Detects cholinergic slowing of the heart
Vitamin B12 500–900 pg/mL Deficiency mimics and worsens memory loss
Homocysteine Below 8 µmol/L Elevated levels track brain atrophy and cognitive decline
TSH 0.5–2.0 mIU/L Thyroid dysfunction is a reversible cause of cognitive complaint
HbA1c 5.0–5.4% Glycemic control tracks long-term cognitive risk
ALT Below 25 U/L (men), below 20 U/L (women) Baseline safety anchor against adulterated products
eGFR Above 90 mL/min/1.73 m² Clearance is largely renal, so falling function raises exposure
MoCA score 26–30 points Objective tracking of the outcome the compound targets

Cadence: Baseline before starting; resting heart rate rechecked at one week and four weeks; cognitive test repeated at four weeks and twelve weeks; full blood panel every 6–12 months while use continues.

Qualitative Assessment

  • Subjective clarity of thought and ease of word retrieval during demanding work
  • Sustained attention span before the first involuntary task switch
  • Dream vividness and number of night-time awakenings
  • Presence of nausea, sweating, excess salivation or muscle twitching
  • Whether the difference is noticeable to a partner or colleague, not only to the user
  • Whether the loss of effect during a planned week off is actually perceptible
Not medical advice. Educational distillation of a single evidence review. Confirm any decision with a qualified clinician, especially in the presence of prescription drugs or chronic conditions.